Discontinuation of thiopurines.

ApprovedSmall molecule

GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Discontinuation of thiopurines. is one of 37 small molecule programs targeting Ulcerative Colitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisApproved

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

2 2

Mesalazine

Ferring

Phase 3

17 3

CP-690,550

Pfizer

Phase 3

2 4

PTM SEMA

Gilead

Phase 3

1 5

JNJ-42756493

RPC1063

2 7

Discontinuation of thiopurines.

GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Approved

1 8

Etrolizumab

Roche

Phase 3

7 9

Simponi

Johnson & Johnson

Preclinical

15 10

CT-P13 SC (infliximab)

CCelltrion

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Ulcerative Colitis

NCT07248644

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Discontinuation of Thiopurine Therapy in Elderly Patients With Ulcerative Colitis

Not yet recruiting·GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa·Phase 4·NCT07248644·304 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Discontinuation of thiopurines.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Discontinuation of thiopurines. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Discontinuation of thiopurines.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Discontinuation of thiopurines.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News